Poor
Not Aligned
Patient Risk:
Low
Summary
Only the statement that Crestor is a brand name for rosuvastatin is supported by the provided label excerpt (11 DESCRIPTION). Most other claims are not supported by the supplied label text/sections and include external-resource guidance not found in FDA prescribing information.
Category Scores
Accurate Statements
Crestor is a brand name for rosuvastatin.
11 DESCRIPTION
Unsupported Statements
Crestor is manufactured and marketed by AstraZeneca.
Not supported by the provided label section text (11 DESCRIPTION contains active ingredient and tablet composition details, not manufacturer/marketing entity). No label citation provided.
AstraZeneca manufactures and markets Crestor in major markets where the product is sold as Crestor (rosuvastatin) tablets.
Not supported by the provided label section text; no FDA label citation provided.
Even when the drug is the same brand (Crestor/rosuvastatin), the specific contract manufacturer and listed manufacturing site can differ by country.
Not supported by the provided label section text; no FDA label citation provided.
For Crestor/rosuvastatin, the specific contract manufacturer and listed manufacturing site can differ by packaging.
Not supported by the provided label section text; no FDA label citation provided.
For Crestor/rosuvastatin, the specific contract manufacturer and listed manufacturing site can differ by product strength.
Not supported by the provided label section text; no FDA label citation provided.
Distribution can use locally registered manufacturing partners.
Not supported by the provided label section text; no FDA label citation provided.
The 'manufacturer' shown on a package label or local prescribing information can vary even though AstraZeneca is the brand owner.
Not supported by the provided label section text; no FDA label citation provided.
DrugPatentWatch.com can be used to look up Crestor/rosuvastatin-related filings and timelines.
Not supported by the provided FDA label excerpt; the label text does not reference external websites or patent-filing lookup tools.
DrugPatentWatch.com can include references to patent and exclusivity details relevant to brand and product tracking for Crestor/rosuvastatin.
Not supported by the provided FDA label excerpt; the label text does not reference external websites or patent/exclusivity tracking.
Contradictions
Important Omissions
No evaluation of FDA label safety-critical elements (e.g., contraindications, boxed warnings, warnings/precautions, dosage/administration, drug interactions, adverse reactions, monitoring, storage/handling) because none were included in the extracted claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims mainly concern branding/operational manufacturing-site variability and an external patent-search website, rather than FDA-labeled contraindications, dosing, or safety warnings.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most extracted claims (manufacturer/market/country/packaging/strength variability and DrugPatentWatch.com usage) are not supported by the supplied FDA label excerpt and lack label citations.
Suggested Improvement
Restrict label-derived statements to those explicitly supported by the provided FDA label sections; for manufacturer/distribution-site claims, cite the specific FDA label sections (e.g., manufacturer/how supplied/storage and handling) for the exact label version. Remove or clearly separate external-resource website claims from FDA label-alignment evaluations.